Active vaccination to prevent de novo hepatitis B virus infection in liver transplantation

Table 1 Published studies with HBsAb titers in patients receiving HBcAb(+) grafts

Study	Patients	Lamivudine/HBIG	Vaccination	HBsAb	DNH	Follow-up
			Pre/post-LT	cutoff (IU/L)		(mo)
Chang et al[24]	9/pediatric	HBIG	Yes/Yes	20	50% vs 0%1	26
Lin et al[18]	30/pediatric	lamivudine	Yes/Yes	1000	15.7% vs 0%	57
Soejima et al[13]	11/adult	HBIG	No/Yes	1000	0%2	15
Park et al[26]	14/pediatric	HBIG	No/Yes	100	7.1%3	26.5
Su et al[25]	36/pediatric	N	Yes/Yes	200	30.7% vs 4.3%	52
Liu et al[28]	41/adult	Lamivudine	Yes/Yes	1000	6.4% vs 0%	52
Lin et al[27]	34/pediatric	N	Yes/Yes	1000	0%4	65

¹Six out of 7 patients had > 200 IU/L;

²All > 1000 IU/L, 4 patients with cessation of HBIG;

³All > 100 IU/L, one patient with 362 IU/L of HBsAb and escape mutant;

⁴All > 1000 IU/L without additional prophylaxis. HBIG: Hepatitis B immunoglobulin; DNH: de novo hepatitis B infection; LT: Liver transplantation.